CONSOL Remains Top Pick in Coal Space and 4 Stock Analyses to Know Now

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Current Price: $177.93

RBC Capital thinks that Regeneron is at an attractive entry point due to its belief that the market is undervaluing the near-term market opportunity of Regeneron’s Eylea treatment along with its broader pipeline. The firm recommends purchasing the stock on pullbacks and it keeps its Outperform rating on the stock.

Markets are off to the races and this stock is on fire. Click here to discover it now!